More recent results on the immunomodulatory effects of Tα1, combined with increased knowledge of host/tumor response to checkpoint inhibitors, has shown the way to future research with Tα1 in cancer therapy that should include, holistically, the response of the tumor, the tumor microenvironment, and the distant sites. The gene discussed is TAAR1; the disease is neoplasm.